Reports Q1 results, discloses neoantigen immunogenicity prediction application
Achilles reported Q1 2023 results with operating expenses of USD 18.6m (USD 19m) and a cash position of USD 158.5m (FY 2022: USD 173.3m) that provides a runway into mid-2025. The company reiterated that clinical and translational data in NSCLC and melanoma should be disclosed in Q4 2023, and that t
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.